Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsWorld’s First Approved Biosimilar toActemra ® Guangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stagebiopharmaceutical company, announced thattheChina National Medical Products Administration(NMPA) hasapproved BAT1806, a biosimilar of Actemra ® (tocilizumab)...
Guangzhou, China --(BUSINESS WIRE)--Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing apipeline of innovative therapies and a pipeline of biosimilars, today announcedthat Jin-Chen Yu, SVP, Research willpresent a talk on BAT8009 (B7-H3-ADC) at the 2nd Annual ADC Target Sele...
Guangzhou, China --(BUSINESS WIRE)--Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing apipeline of innovative therapies and a pipeline of biosimilars, today announcedthe company will present two posters at the 2022 San Antonio Breast CancerSymposium (SABCS) taking place De...
